|
Characteristics
|
No. (%)
|
|---|
|
All patients
|
104 (100)
|
|
Age (years; mean 56.2)
| |
|
≤ 50
|
33 (32)
|
|
51–60
|
29 (28)
|
|
>60
|
42 (40)
|
|
Menopause
| |
|
Premenopausal
|
30 (29)
|
|
Postmenopausal
|
74 (71)
|
|
Grade
| |
|
2
|
71 (68)
|
|
3
|
33 (32)
|
|
pTb
| |
|
1
|
17 (16)
|
|
2
|
86 (83)
|
|
4
|
1 (1)
|
|
pNb
| |
|
0
|
29 (28)
|
|
1
|
75 (72)
|
|
pMb
| |
|
0
|
104 (100)
|
|
Stageb
| |
|
I
|
3 (3)
|
|
IIa
|
40 (38)
|
|
IIb
|
60 (58)
|
|
IIIb
|
1 (1)
|
|
Histology
| |
|
Ductal
|
103 (99)
|
|
Scirrhous
|
1 (1)
|
|
Therapya
| |
|
Tamoxifen
|
70 (67)
|
|
Radiotherapy
|
51 (49)
|
|
Cyclophosphamide/Methotrexate/5-Fluorouracil
|
28 (27)
|
|
Cyclophosphamide/Adriamycin/5-Fluorouracil
|
1 (1)
|
|
Cyclophosphamide/Adriamycin
|
1 (1)
|
|
Progesterone
|
1 (1)
|
|
Letrozol
|
1 (1)
|
- aSome patients received more than one special treatment.
- bAccording to [15]
